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We can no longer
rely on a decreasing
number of FDA-
sanctioned trials for
coverage of our
patients, because
too many Medicare
patients do not
qualify for these
clinical trials.
To break this log
jam, and reach the
CMS bar of “rea-
sonable and neces-
sary,” some have
proposed linking
expanded coverage
of CAS with a
mandate for pa-
tient data
collection.EDITOR’S PAGE
Catch-22: Carotid Stenting Is Safe and Effective
(Food and Drug Administration)
But Is it Reasonable and Necessary
(Centers for Medicare and Medicaid Services)?
It is time once again for the Centers for Medicare and Medicaid Services (CMS) to reconsider
the National Coverage Determination (NCD) for carotid artery stenting (CAS) in light of:
1) the completion of CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial),
the largest prospective, multicenter, randomized controlled trial of carotid endarterectomy
(CEA) versus CAS in average surgical risk patients (1); 2) approval by the U.S. Food and
Drug Administration (FDA) of CAS systems for symptomatic and asymptomatic patients; and
) publication of 2 multisocietal professional guideline documents supporting CAS as an ap-
ropriate alternative to CEA with a Level I recommendation in symptomatic patients, and a
evel II recommendation in asymptomatic patients (2,3). The timing of this determination is critical
o patient access for CAS, as several industry-sponsored post-market extension studies have closed
CABANA [Carotid Stenting Boston Scientific Surveillance Program], Boston Scientific Corp.,
aple Grove, Minnesota) or will be closing soon (CHOICE [Carotid Stenting For High Surgical-
isk Patients; Evaluating Outcomes Through The Collection Of Clinical Evidence], Abbott Vas-
ular, Santa Clara, California), putting Medicare beneficiaries in a difficult position.
To understand the importance of the upcoming coverage decision by CMS, we need to review
he history of CAS reimbursement. As philosopher George Santayana said “those who cannot
emember the past are condemned to repeat it (4).” The standard to be met for CMS coverage is
reasonable and necessary,” which stakeholders struggle to understand because it has never been
efined. The fact that 2 government agencies (FDA  safe and effective; and CMS  reasonable
nd necessary) have distinctly different mandates has the makings of a “Catch-22” situation.
In the mid-1980s, the CMS issued a national noncoverage decision for angioplasty of
bstructive lesions of the carotid, vertebral, and cerebral arteries (5). In 2001 and 2004, the
CD was expanded to allow coverage for CAS as part of an FDA-approved Category B
nvestigational Device Exemption (IDE) trial, and to FDA-sanctioned post-approval trials. In
005, the CMS further expanded coverage to include high surgical risk symptomatic patients
ith 70% to 99% carotid artery stenosis treated with FDA-approved devices. In October of 2008,
he CMS declined to expand coverage for high surgical risk seniors, stating there was inadequate
eer-reviewed literature to support such a change. Following the publication of studies with over
,000 high surgical risk patients in 2009, (SAPPHIRE Worldwide [Stenting and Angioplasty
ith Protection in Patients At High-Risk for Endarterectomy], Cordis Corp., Miami Lakes,
lorida [n  2,001] [6], CAPTURE-2 [Carotid RX ACCULINK(TM)/ACCUNET(TM) Post-
pproval Trial to Uncover Unanticipated or Rare Events], Abbott Vascular, Santa Clara, California
n  4,175], and EXACT [Emboshield and Xact Post Approval Carotid Stent Approval, Abbott
ascular] [n  2,145] [7]), with excellent results, the CMS reopened the carotid NCD for
he seventh time but once again failed to expand coverage.
Dr. White has reported that he has no relationships relevant to the contents of this paper to disclose. Dr. Jaff is a Non-Compensated Advisor
for Abbott Vascular, Cordis Corporation, Covidien Vascular, and Medtronic Vascular; and is a Member, Board of Directors for VIVA
Physicians, a 501 c 3 not-for-profit education and research organization.
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695There are multiple special interest groups (physicians
[surgeons, neurologists, cardiologists, and radiologists], the
medical device industry, and health insurers) trying to
influence the government to expand or restrict CAS
coverage. The fact that there is such strong disagreement on
both sides of the CAS versus CEA controversy among
physician stakeholders is strong evidence for equipoise (8,9).
owever, given our responsibility as physicians to provide
he best care for patients, we must put aside our “personal
nterests.” The published, peer-reviewed evidence supports
AS as a reasonable alternative to CEA in both high and
verage surgical risk patients as reflected in the American
eart Association (AHA) and American Stroke Association
ASA) guidelines document (3) and the broad multisociety
uidelines endorsed by 14 stakeholder professional societies
2). The largest randomized trial of CAS versus CEA ever
erformed showed no difference in the overall stroke rate
etween CAS and CEA (1). With increasing experience,
here has been dramatic improvement in CAS outcomes
ver time (9–11). As responsible physicians, we know that
rocedures such as CEA and CAS have better outcomes
hen patients are carefully selected, and experienced and
killed operators perform the procedures in experienced
enters. To take advantage of this opportunity for tailored
herapy in the patients most likely to benefit requires the
bility to choose between CEA or CAS.
The debate about effective alternatives for the treatment
f carotid artery stenosis has moved beyond
evascularization, as some contend that improved medical
herapy is now equivalent, if not superior, to
evascularization (11). While this hypothesis is attractive,
he current evidence is far from conclusive. There are no
andomized, multicenter, prospective trials of optimal
edical therapy (including pill counts for patient
ompliance, rates of treatment to goal, or independent
edical therapy adjudication committees) as primary
reatment for “revascularization-eligible” patients. A major
hange in evidenced-based stroke prevention strategies
ill require clinical trial data. The short-cut of simply
xtrapolating data from atherosclerotic coronary artery
rials could lead to serious errors.
To break this log jam, and reach the CMS bar of
reasonable and necessary,” some have proposed linking
xpanded coverage of CAS with a mandate for patient
ata collection. For example, symptomatic patients with
arotid stenosis 50% by angiography (or 70% by
ultrasound, magnetic resonance angiography [MRA], or
computed tomography angiography [CTA]), would be
eligible for reimbursement for CAS with: 1) mandatoryfacility certification by an independent accrediting
organization; 2) participation in a national prospective
registry with collection of minimum data elements (i.e.,
National Institutes of Health Stroke Scale [NIHSS]
determination before and at 30 days following the
procedure, and minimum facility and operator
experience); and 3) site- and operator-level outcomes
analyses required for reporting and accreditation.
Asymptomatic patients with carotid stenosis 60% by
angiography (or 70% by ultrasound, or 80% by MRA or
CTA) would be held to a higher bar for reimbursement. In
addition to the requirements for symptomatic patients,
centers that treat asymptomatic patients would also be
subjected to an independent audit, by an accrediting body,
to verify the accuracy of the reported data. Similar to
post-market surveillance studies, approximately 1 in 10
records (10%) would be audited. Sites with data quality
problems would be reported to the appropriate
independent accrediting body, potentially resulting in loss
of CAS privileges.
We can no longer rely on a decreasing number of
FDA-sanctioned trials for coverage of our patients,
because too many Medicare patients do not qualify for
these clinical trials. The patient’s plight is similar to the
ancient mariner’s “water, water, everywhere and not a
drop to drink.” While there are multiple FDA-approved
“safe and effective” CAS systems available, only a tiny
fraction of Medicare patients are covered by the CMS
“reasonable and necessary” standard. We have
multispecialty guidelines supporting CAS as an alternative
to CEA in selected patients (2,3). The largest randomized
carotid stenosis trial ever performed (CREST) supports
equivalence for CEA and CAS (1). This begs the
question: what more can be done?
Has CMS raised the bar of “reasonable and necessary”
to unattainable levels, hiding behind a shield of physician
disagreement to “ration healthcare” by denying expansion
of CAS coverage to be equivalent with CEA? Or is this
simply the CMS using the “Catch-22,” to deny American
seniors access to therapy they should “reasonably and
necessarily” have available to them?
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